🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 20 of 116

  1. Rituximab (RTX)

    Incyte

    Diffuse Large B-cell Lymphoma

    phase 3 small molecule completed

    1 trial

  2. Rituximab 375 mg/m^2

    Takeda

    Mantle Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  3. RoActemra 20 mg/mL concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Neulasta 6 mg solution for injection, AZD0486, RoActemra 20 mg/mL concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Ribodoxo® 2 mg/ml Injektionslösung, Prednison 20 mg GALEN®, AZD0486, Endoxan 500 mg, poeder voor oplossing voor injectie, Ruxience 500 mg concentrate for solution for infusion

    AstraZeneca AB

    Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  4. Robotic Gastrectomy

    The First People's Hospital of Lianyungang

    Gastric Cancer (GC)

    phase 3 other active

    1 trial

  5. Ropivacaine HCL

    Atrium Therapeutics

    Renal Carcinoma

    phase 3 small molecule active

    1 trial

  6. Roux-en-Y anastomosis

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 3 other active

    1 trial

  7. Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE

    Hoffmann-La Roche

    This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally

    phase 3 small molecule active

    1 trial

  8. Rucaparib

    pharmaand GmbH

    Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  9. S-1 therapy

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    1 trial

  10. SALINE, GEMCITABINE, GEMCITABINE, Quemliclustat, GEMCITABINE, PACLITAXEL ALBUMIN-BOUND

    Arcus Biosciences

    Pancreatic cancer, Metastatic Pancreatic ductal adenocarcinoma (mPDAC), Pancreatic ductal adenocarcinoma (PDAC)

    phase 3 small molecule active

    1 trial

  11. SBRT

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 3 other active

    3 trials

  12. SELINEXOR, Selinexor placebo for 20 mg tablets is formulated for oral administration. selinexor placebo tablets are film coated bi-convex round tablets

    Karyopharm Therapeutics Inc

    endometrial cancer

    phase 3 small molecule active

    1 trial

  13. SELPERCATINIB, CARBOPLATIN , SELPERCATINIB, PEMBROLIZUMAB, CISPLATIN , PEMETREXED

    Eli Lilly Co.

    Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  14. SGM-101

    BRIGHT MINDS BIOSCIENCES INC.

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  15. SHR-A2009 ; Aumolertinib

    Suzhou Ribo Life Science Co.

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  16. SODIUM CHLORIDE, MYCOPHENOLATE MOFETIL, GLUCOSE, Oleclumab, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion., Monalizumab, IMFINZI 50 mg/mL concentrate for solution for infusion., INFLIXIMAB

    AstraZeneca AB

    Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  17. SODIUM CHLORIDE, ROPIVACAINE

    Pari Pharma GmbH

    Cancer surgery

    phase 3 small molecule active

    1 trial

  18. SOTORASIB, Dexamethasone 2mg Tablets, DOCETAXEL

    Amgen

    Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation

    phase 3 small molecule active

    1 trial

  19. SOTORASIB, Stivarga 40 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets

    Amgen

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  20. SR-A + Epratuzumab

    United Therapeutics Europe Ltd

    Acute Lymphoblastic Leukemia (ALL)

    phase 3 small molecule completed

    1 trial

  21. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  22. SV-BR-1-GM

    BriaCell Therapeutics

    Breast Cancer

    phase 3 mab active

    2 trials

  23. SYLVANT 400 mg powder for concentrate for solution for infusion, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, ENZALUTAMIDE, AMG 509, AMG 509, CABAZITAXEL

    Amgen

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  24. Sacituzumab Govitecan-hziy

    Gilead Sciences Ireland UC

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  25. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Non Small Cell Lung Cancer

    phase 3 mab active

    1 trial

  26. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 mab active

    2 trials

  27. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Breast Neoplasms

    phase 3 small molecule active

    1 trial

  28. Sasanlimab

    Pfizer Australia Pty Ltd

    Non-Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  29. Savolitinib

    AstraZeneca

    Carcinoma

    phase 3 small molecule active

    1 trial

  30. Selinexor

    Karyopharm Therapeutics Inc

    Endometrial Cancer

    phase 3 small molecule active

    2 trials

  31. Selinexor

    Karyopharm Therapeutics Inc

    Dedifferentiated Liposarcoma

    phase 3 small molecule completed

    1 trial

  32. Selinexor (combination therapy)

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  33. Selpercatinib

    Eli Lilly and Company

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  34. Sevabertinib

    Bayer HealthCare AG

    Advanced Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  35. Sigvotatug Vedotin

    Pfizer

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  36. Somatostatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gallbladder Neoplasms

    phase 3 small molecule completed

    1 trial

  37. Sonrotoclax

    BEONE MEDICINES AUS PTY LTD

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial

  38. Sonrotoclax

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    4 trials

  39. Soquelitinib

    Corvus Pharmaceuticals

    Peripheral T-Cell Lymphoma, Not Otherwise Specified

    phase 3 small molecule active

    1 trial

  40. Sorafenib

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  41. Sorafenib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 3 small molecule active

    2 trials

  42. Sorafenib (Nexavar, BAY43-9006)

    Bayer HealthCare AG

    Carcinoma

    phase 3 small molecule completed

    1 trial

  43. Sorafenib (Nexavar, BAY43-9006)

    Bayer HealthCare AG

    Carcinoma, Hepatocellular

    phase 3 small molecule completed

    1 trial

  44. Standard First-Line Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unresectable Colorectal Cancer

    phase 3 small molecule active

    1 trial

  45. Standard of Care

    AbbVie

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  46. Standard of Care

    Telix Innovations

    Metastatic Prostate Cancer

    phase 3 small molecule terminated

    1 trial

  47. Standard treatment: Control arm

    United Therapeutics Europe Ltd

    Cervical Carcinoma

    phase 3 other active

    1 trial

  48. Subcutaneous Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Metastatic Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.